For those of you attending the GPU Technology Conference (GTC) next week, we want to extend an invitation to our closing night party for charity on Thursday, September 23. The event will feature live music and raffle prizes, all for a great cause, Hope Lab. In addition, every dollar raised at the event will be matched by the NVIDIA Foundation.

Tickets to the event cost $10, which includes a free drink ticket plus an entry into a raffle. You can buy your party tickets on the GTC show floor, at the NVIDIA Foundation table on the concourse, or at the door.

About the cause: This year's recipient is Hope Lab, an organization that aims to enhance the physical health and psychological well-being of young people with cancer. Your donations will support the global distribution of Hope Lab's popular kids video game, Re-Mission, the first video game shown to induce positive behaviors that enhance the effectiveness of medical treatment. In Re-Mission, players pilot a nanobot named Roxxi as she travels through the bodies of fictional cancer patients destroying cancer cells, battling bacterial infections, and managing side effects associated with cancer and cancer treatment. Research shows that patients who played Re-Mission stuck to their prescribed treatments more consistently, a key component of successful cancer treatment, and showed increases in cancer knowledge and self-efficacy. Get your own copy at: www.re-mission.net.

About the NVIDIA Foundation:

The NVIDIA Foundation is one of the only employee-led foundations in Silicon Valley. Each year, an employee board of directors receives feedback from our global employee population regarding the issues they care most about addressing, such as education and cancer research, and puts together an exciting set of programs that leverages NVIDIA's unique strengths as a company: having a transformative impact, engaging our employees, leveraging our ecosystem of customers, suppliers and vendors. The Foundation is developing a program called Compute the Cure, to drive forward a cure for cancer by supporting researchers working with gene sequencing technologies.